SRDAN VERSTOVSEK to Antibodies, Monoclonal, Murine-Derived
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Antibodies, Monoclonal, Murine-Derived.
Connection Strength
0.079
-
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
Score: 0.018
-
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80.
Score: 0.014
-
Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62.
Score: 0.014
-
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003 Nov 15; 102(10):3514-20.
Score: 0.011
-
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20.
Score: 0.011
-
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5.
Score: 0.011